A go-ahead for an anti-cancer drug

Wiener, Leonard; Smith, Anne Kates
January 1993
U.S. News & World Report;1/11/93, Vol. 114 Issue 1, p67
Announces that the drug Taxol, derived from the bark of the Pacific yew tree, won Food and Drug Administration approval last week for the treatment of advanced ovarian cancer. The benefits of the drug; Conditions of the FDA action; Cost for a typical course of Taxol; The purpose of drug-maker Bristol-Myers Squibb's new Taxol Patient Access Program; Telephone number to call for more information.


Related Articles

  • Dateline Washington.  // Consumers' Research Magazine;Jan1993, Vol. 76 Issue 1, p6 

    Reports that an advisory committee of the Food and Drug Administration (FDA) has recommended that the drug Taxol be approved to treat women with ovarian cancer who have failed to respond positively to at least one other chemotherapy treatment. Details.

  • More women have access to taxol.  // FDA Consumer;Dec92, Vol. 26 Issue 10, p2 

    Reports that more women with advanced ovarian cancer have access to taxol under the Food and Drug Administration's expansion of a previously authorized experimental program. FDA's expansion of the program last September; Increased supplies of taxol; Better understanding of how to manage the...

  • Taxol approved to treat ovarian cancer.  // FDA Consumer;Mar1993, Vol. 27 Issue 2, p2 

    Reports that a new drug was added to the arsenal of agents in the battle against ovarian cancer last Dec. 29, 1992, when the Food and Drug Administration approved Taxol (paclitaxel) for advanced cases of the disease that have not responded to other therapies or have progressed after treatment. ...

  • FDA backs Taxol.  // Health News & Review;1993, Vol. 3 Issue 2, p23 

    Reports on the Food and Drug Administration's approval of Taxol, an anti-cancer drug. Pacific Northwest yew tree; Treatment of ovarian cancer; Reduction of tumor size; Similarity of side-effects to other anti-cancer drugs.

  • In vitro studies of taxol as a radiation sensitizer in human tumor cells. Liebmann, James; Cook, John A. // JNCI: Journal of the National Cancer Institute;3/16/94, Vol. 86 Issue 6, p441 

    Assesses the in vitro radiosensitization properties of paclitaxel in human tumor cell lines. Use of clonogenic assays to determine the effect of paclitaxel concentrations; Definition of cell cycle characteristics after treatment with paclitaxel; Variations in the degrees of radiosensitization...

  • Semisynthetic Taxol goes on market amid ongoing quest for new versions. McNeil, Caroline // JNCI: Journal of the National Cancer Institute;8/2/95, Vol. 87 Issue 15, p1106 

    Reports on the distribution of the first semisynthetic version of paclitaxel (Taxol) in the US market. Phasing in of semisynthetic paclitaxel in mid-1995; Concerns over the bark-based process of Taxol; Approval of the US Food and Drug Administration on the use of Taxus baccata; Benefit of cell...

  • Taxol: Search for a cancer drug. Joyce, Christopher // BioScience;Mar1993, Vol. 43 Issue 3, p133 

    Describes the benefits of the natural drug, taxol, on the fight against cancer. The Food and Drug Administration (FDA) has approved the drug for general use in advanced ovarian cancer. Taxol was discovered in 1963; Where taxol stands now; How taxol attacks cancer; Conservation concerns for the...

  • Good for yew. Gutfeld, G.; Rao, L. // Prevention;Feb92, Vol. 44 Issue 2, p18 

    Reports that Taxol, a new drug culled from yew tree bark, is now being used in advanced breast cancer. A potent fighter against ovarian cancer; Study; Results; Possible extraction of the drug from needles of various taxus species.

  • Cancer and yew. Bowker, M. // Environmental Action;Sep/Oct91, Vol. 23 Issue 2, p7 

    Discusses the dilemma concerning a new anti-cancer drug called taxol, developed in 1989, which is made from the bark of the Pacific yew tree. Harvesting would destroy the natural habitat of the endangered northern spotted owl; Involvement of the US Department of Agriculture and the National...

  • Treatment IND for taxol.  // FDA Consumer;Oct92, Vol. 26 Issue 8, p3 

    Reports that under the new treatment IND, more women with advanced ovarian cancer will have access to the experimental drug taxol. The Food and Drug Administration authorized a treatment IND/group C protocol for taxol last July 17. Eligibility standards to take the drug that must be met; The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics